Lilly says depression drug didn’t meet goal in three studies – chicagotribune.com


Eli Lilly & Co. will end development of the depression medicine edivoxetine as an add-on therapy after the drug failed to meet goals in three studies.A current trial evaluating the experimental compound’s long-term effects will continue, the Indianapolis-based company said in a statement Thursday. Edivoxetine was in the final of three stages of testing usually required for marketing approval by U.S. regulators.

via Lilly says depression drug didn't meet goal in three studies – chicagotribune.com.